Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program

OBJECTIVES: A new patient assistance program (PAP) for pembrolizumab was started in China in 2021. The researchers aimed to evaluate the economic outcomes of pembrolizumab plus pemetrexed and platinum versus chemotherapy alone in the first-line treatment of patients with metastatic non-squamous non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yuanyi, Hui, Wen, Zhu, Min, Zhang, Mingyue, Gao, Zhixiang, Wu, Huazhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661036/
https://www.ncbi.nlm.nih.gov/pubmed/34900717
http://dx.doi.org/10.3389/fonc.2021.768035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661036/
https://www.ncbi.nlm.nih.gov/pubmed/34900717
http://dx.doi.org/10.3389/fonc.2021.768035

Ejemplares similares